FGFR2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P10848(FGFR2 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P10848(FGFR2 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Fibroblast Growth Factor Receptor 2 (FGFR2) is a transmembrane tyrosine kinase receptor that plays critical roles in embryonic development, tissue repair, and cellular processes such as proliferation, differentiation, and angiogenesis. Dysregulation of FGFR2 signaling, caused by gene amplification, mutations, or overexpression, is implicated in various cancers, including breast, gastric, and endometrial cancers. FGFR2-targeted antibodies are therapeutic agents designed to block aberrant FGFR2 activity by binding to specific extracellular domains, inhibiting ligand-dependent receptor activation or promoting receptor internalization.

Monoclonal antibodies (e.g., bemarituzumab) selectively target FGFR2 isoforms or overexpressed variants, often sparing other FGFR family members to reduce off-target effects. These antibodies may also be conjugated to cytotoxic payloads for enhanced tumor-specific killing. Preclinical and clinical studies highlight their potential in tumors with FGFR2 alterations, though challenges like resistance mechanisms and tumor heterogeneity persist.

Research continues to optimize antibody specificity, explore combination therapies with chemotherapy or immune checkpoint inhibitors, and identify predictive biomarkers for patient stratification. FGFR2 antibodies represent a promising precision oncology approach, particularly in malignancies where FGFR2 dysregulation drives oncogenic progression.